RxDoctor Payments Data

Gary Bevill, MD

Family Medicine · El Dorado, ARNPI 1538154570

Payments from drug & device makers

$1,670in general payments, 2019–2025

Across 104 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$415
  • Novo Nordisk$193
  • GSK$143
  • AbbVie$135
  • Merck$116
  • Medtronic$103
  • plus $565 from 17 others

What the payments were for

  • Food & beverage$1,60596%
  • Education$654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,670 in reported general payments places this provider in the 65th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$345,317
Medicare patients
692
Services billed
11,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban233$89,768
JanuviaSitagliptin Phosphate44$47,874
JardianceEmpagliflozin70$34,328
XareltoRivaroxaban97$30,308
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog54$22,225
JanumetSitagliptin Phos/Metformin Hcl50$20,617
OzempicSemaglutide15$14,485
Tresiba Flextouch U-200Insulin Degludec23$13,903
Potassium Chloride426$10,959
Breo ElliptaFluticasone/Vilanterol22$10,856
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$9,415
EntrestoSacubitril/Valsartan18$8,004
SynjardyEmpagliflozin/Metformin Hcl12$6,282
Gabapentin406$5,578
GemtesaVibegron21$5,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$89,768233 claims
MerckJanuvia, Janumet$116$68,49194 claims
Johnson & JohnsonXarelto$11$30,30897 claims
GSKBreo Ellipta, Trelegy Ellipta$143$20,27140 claims
Novo NordiskOzempic, Novolog$193$17,96545 claims
AbbVieLinzess, Synthroid$135$9,05675 claims
NovartisEntresto$26$8,00418 claims
AstraZenecaBrilinta$30$2,84712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in El Dorado

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →